Camurus raises financial guidance for the full year 2023
Lund — 23 October 2023 — Camurus today announced revised full year 2023 outlook for the company’s total revenues and profit before taxes. Camurus’ guidance for total revenues is increased to SEK 1,640–1,720 million from SEK 1,530–1,650 million. Profit before taxes is expected in the range SEK 525–600 million, previously SEK 425–525 million.
The update is the result of positive revenue performance, margin improvement and currency effects.
Detailed financial results will be presented in Camurus’ Interim Report for the third quarter 2023 on 9 November 2023.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
[email protected]
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
[email protected]
About Camurus
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
This is information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the managing director, at 5:45 pm CET on 23 October 2023.
